What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His primary scientific interests are in Internal medicine, Oncology, Surgery, Chemotherapy and Breast cancer.
His study in Hazard ratio, Cancer, Lung cancer, Clinical endpoint and Metastatic breast cancer is done as part of Internal medicine.
The concepts of his Hazard ratio study are interwoven with issues in Colorectal cancer, KRAS, Panitumumab and Epidermoid carcinoma.
His Oncology research is multidisciplinary, incorporating perspectives in Survival rate, Pathology, Carboplatin, Proportional hazards model and Docetaxel.
His Surgery research is multidisciplinary, incorporating elements of Placebo, Clinical trial and Carcinoma.
His biological study spans a wide range of topics, including Gynecology and Chemotherapy regimen.
His most cited work include:
- Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck (3893 citations)
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (1828 citations)
- A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer. (1568 citations)
What are the main themes of his work throughout his whole career to date?
Jacek Jassem spends much of his time researching Internal medicine, Oncology, Breast cancer, Lung cancer and Surgery.
Jacek Jassem works mostly in the field of Internal medicine, limiting it down to concerns involving Gastroenterology and, occasionally, Phases of clinical research.
His study in Oncology is interdisciplinary in nature, drawing from both Hazard ratio, Trastuzumab, Stage and Pathology.
His research in Breast cancer intersects with topics in Adjuvant, Gynecology, Brain metastasis and Primary tumor.
His Lung cancer research is multidisciplinary, relying on both Respiratory disease, Cancer research and Carcinoma.
As part of his studies on Surgery, he often connects relevant areas like Placebo.
He most often published in these fields:
- Internal medicine (61.51%)
- Oncology (52.12%)
- Breast cancer (22.49%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (61.51%)
- Oncology (52.12%)
- Lung cancer (20.37%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Oncology, Lung cancer, Breast cancer and Cancer research are his primary areas of study.
Many of his studies involve connections with topics such as Surgery and Internal medicine.
His Oncology research incorporates elements of Chemotherapy naive, Brain metastasis, Atezolizumab, Primary tumor and Radiation therapy.
His Lung cancer research includes themes of Blood proteins and Gene dosage.
Jacek Jassem works mostly in the field of Breast cancer, limiting it down to topics relating to Immunohistochemistry and, in certain cases, Salivary gland, Fusion gene, Anaplastic lymphoma kinase and Exon.
His Cancer research research includes elements of Molecular biology, Carcinoma and Adenocarcinoma.
Between 2014 and 2021, his most popular works were:
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial (1199 citations)
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial (753 citations)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (494 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Jacek Jassem mainly focuses on Internal medicine, Oncology, Breast cancer, Chemotherapy and Hazard ratio.
His Internal medicine study incorporates themes from Placebo and Surgery.
He interconnects Area under the curve, Prostate cancer, Docetaxel, Nivolumab and Radiation therapy in the investigation of issues within Oncology.
His Breast cancer research includes elements of Primary tumor and Brain metastasis.
As a member of one scientific family, he mostly works in the field of Chemotherapy, focusing on Monoclonal antibody and, on occasion, Neuroendocrine tumors.
His studies in Hazard ratio integrate themes in fields like Gastroenterology and Lenvatinib.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
